Bold claim first: Rigorous science at Yale is changing stroke outcomes in ways the field rarely dared imagine. If you think strokes are a grim, fixed fate, this article will challenge that assumption and show how careful research can rewrite what’s possible for patients.
On a Friday in 2023, Gillian Goldrich’s life pivoted in an instant. While dining, her husband noticed she couldn’t bring her spoon to her mouth. “One minute I was fine, the next I was having a stroke,” she recalls. An ischemic stroke, caused by a clot blocking a major brain artery, rapidly unfolded. In line with the familiar Act F.A.S.T. guidance, her face drooped, an arm faltered, and speech slurred. The imperative was simple and urgent: time matters.
Goldrich, then 63 and in excellent health, had been told just months earlier that her lifetime risk of stroke was about 1.3%. After the event, the odds of regaining her former function stood at 1 in 4. Those numbers might appear modest, yet they are encouraging compared with decades past. A stroke victim 20 years ago often faced lasting, profound disability. Today, for every four patients treated, one recovers to their pre-stroke state.
Pooja Khatri, MD, Albert E. Kent Professor of Neurology and Chair of Neurology at Yale, emphasizes this improvement: “It’s remarkable that for every four patients we treat, one regains their pre-stroke condition.” Yet she and colleagues are quick to note that three out of four individuals still live with disabilities, underscoring the urgency of better solutions. Although acute treatments—medications administered immediately after a stroke to protect the brain—hold promise, developing them has proven difficult. Kevin Sheth, MD, a Yale neurology and neurosurgery professor, explains that there has never been a brain-targeted acute stroke drug before now. He also directs Yale’s Center for Brain and Mind Health and serves as Yale Medicine’s neurology and neurosurgery translational research leader.
One hopeful avenue is glyburide, a diabetes drug being explored for its potential to limit brain swelling after a stroke. Early results are promising, but such success remains unusual at this stage of research. While several treatments show potential in animal studies, they frequently fail to translate into human benefit.
To improve the odds, Yale researchers are building new therapies and, crucially, robust systems to test them in ways that better predict human outcomes. This involves collaboration with experts nationwide and a shift in how stroke research is conducted, aiming for even greater patient gains in the coming decades.
A translational stroke research network takes shape
In 2012, Lauren Sansing, MD, a Yale neurologist and associate chair, attended a National Institute of Neurological Disorders and Stroke (NINDS) meeting to diagnose why stroke therapies stagnated. The consensus was stark: preclinical rodent models were not representative of real patients. Most animal studies used young, male, otherwise healthy animals, neglected common comorbidities like diabetes and hypertension, and ignored factors such as age and sex that influence stroke outcomes.
Responding to this gap, the NIH established the Stroke Preclinical Assessment Network (SPAN) in 2019. SPAN brings six sites and a coordinating center together to apply standardized, cross-site testing of acute stroke treatments in animals. Researchers submit candidates to SPAN, which then screens them across the network for consistency and real-world applicability. It’s a model akin to a clinical trial, but with animals, notes Sansing, who leads Yale’s SPAN site.
SPAN deliberately uses a diverse range of rodents—varying in age, sex, and health conditions like hyperglycemia and hypertension—to mirror patient diversity. Variability across sites, usually a problem, becomes an asset here because a treatment must prove beneficial across different biological contexts before advancing to human trials.
In the first SPAN round, six compounds were tested; uric acid emerged as protective after stroke. The results, published in Stroke, set the stage for clinical testing in humans.
Rethinking how stroke trials are conducted
Clinical trials are being redesigned to move faster and scale up more efficiently. NIH StrokeNet creates a stable pipeline that lets researchers initiate more trials, at greater scale, without rebuilding infrastructure each time. This accelerates funding, start times, and patient recruitment.
Yale plays a central role as one of StrokeNet’s 27 regional coordinating centers, with Sheth guiding the Yale region. Investigators can bring trial ideas to StrokeNet, which helps refine them and submit NIH grant proposals. If funded, StrokeNet mobilizes about 500 affiliated hospitals to participate.
The result is more opportunities for patients to participate in meaningful studies, such as the ASPIRE trial, which investigates blood-thinning strategies in hemorrhagic stroke, and the STEP trial, a platform designed to test multiple new interventions in parallel to determine which improvements actually work.
Sansing envisions uric acid moving into STEP’s clinical testing, leveraging SPAN’s streamlined approach to shorten the journey from discovery to clinical reality by years.
“By making SPAN a platform for testing diverse therapies and fast-tracking promising candidates into STEP, we could drastically shorten the pathway from discovery to a positive clinical trial,” Sansing asserts.
Explorations in genetics illuminate new directions
Guido Falcone, MD, ScD, Yale neurologist and director of clinical research in neurocritical care, studies genetic variants linked to stroke risk. An Annals of Neurology study connected genetic predisposition to high blood pressure with poorer blood pressure control and higher stroke risk, even among individuals on treatment. A Neurology study similarly found that genetic susceptibility to hyperlipidemia correlates with worse outcomes for ischemic stroke survivors. These insights help researchers “emulate” real clinical trials in the lab, increasing the odds that a treatment will work in people.
Falcone’s group demonstrated that people genetically predisposed to lower lipid levels may face higher risk of hemorrhagic stroke when lipid-lowering therapies are involved. This line of evidence underpins an ongoing StrokeNet-backed trial examining whether reducing cholesterol-lowering medication after a brain bleed improves outcomes.
A patient story with implications beyond one life
For Goldrich, the rapid pace of research and ready access to trials proved pivotal. At Yale New Haven Hospital, she joined the THUNDER trial, testing a novel clot-removal device. A catheter traveled from her groin to her brain, where intermittent suction extracted the clot. Surgeons aim for complete clot removal in a single pass, which can lead to better recovery. Dr. Charles Matouk, who led the trial, explains that intermittent aspiration may boost efficiency and single-pass success.
Less than a day after the stroke, Goldrich was awake, sitting up, and knitting. Today she participates in Zumba, walks daily, and reports function nearly identical to her pre-stroke self. Her gratitude extends to the clinicians who enrolled her early, recognizing her potential as a trial candidate.
Her experience fuels ongoing commitment to research and peer support. She remains active in recovery groups and continues contributing to stroke research, driven by the desire to help future patients benefit from faster, smarter trials.
If the Yale approach continues to blend rapid clinical testing with rigorous preclinical work, more patients could ride the wave of advancements that redefine stroke recovery—and eventually convert hopeful findings into everyday care. The questions worth pondering are: should the research community embrace even bolder, faster pathways in the name of patient lives, or does speed risk overlooking critical safety hurdles? How should clinicians, patients, and researchers balance rapid progress with careful caution in the hunt for transformative therapies?
